Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing
Sponsor: University of Alabama at Birmingham
Summary
The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic attack (TIA) patients during their hospital stay.
Official title: Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing in Patients With Minor Stroke or High Risk TIA (CYP2C19 and Stroke)
Key Details
Gender
All
Age Range
18 Years - 89 Years
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2025-04-09
Completion Date
2029-04-01
Last Updated
2025-04-24
Healthy Volunteers
No
Conditions
Interventions
CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)
CYP2C19 is a gene that encodes an enzyme responsible for metabolizing several medications, including the antiplatelet drugs.
Locations (1)
University of Alabama at Birmingham
Birmingham, Alabama, United States